Home » Vermillion, Quest Ink Deal to Sell OVA1 in India

Vermillion, Quest Ink Deal to Sell OVA1 in India

Apr 04, 2011

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Vermillion today announced an agreement with Quest Diagnostics for the launch of the OVA1 ovarian cancer test in India.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Bit of Uncertainty

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Effect of Sex

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Better Microbes

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

This Week in PNAS

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.

What's Popular?

In Diagnostics

  1. Myriad Genetics Signs Pricing Agreement With United Healthcare for Several Tests

  2. Interpace Diagnostics Closes $12.2M Public Offering

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.